HWHG(SH:600079)2023-04-27 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 6,225,735,090.21, representing a year-on-year increase of 20.08%[4] - The net profit attributable to shareholders decreased by 27.24% to CNY 665,316,964.81 compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 63.89% to CNY 508,455,478.82[4] - The basic earnings per share for Q1 2023 was CNY 0.41, down 28.07% year-on-year[4] - The weighted average return on net assets was 4.32%, a decrease of 2.50 percentage points compared to the previous year[4] - In Q1 2023, the company reported a net profit of ¥861,113,526.51, a decrease of 17.1% compared to ¥1,038,600,142.33 in Q1 2022[18] - The total comprehensive income for Q1 2023 was ¥862,696,980.10, down from ¥1,021,020,174.67 in Q1 2022[19] - Basic earnings per share decreased to ¥0.41 from ¥0.57 in the previous year[19] - Net profit for Q1 2023 was CNY 73,596,460.78, a significant recovery from a net loss of CNY 6,920,930.12 in Q1 2022[30] - Operating profit for Q1 2023 was CNY 73,377,418.58, compared to an operating loss of CNY 7,055,233.79 in the same period last year[30] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -518,077,556.04, indicating a cash outflow[4] - The company experienced a net cash outflow from operating activities of ¥518,077,556.04, compared to a smaller outflow of ¥35,747,537.28 in Q1 2022[22] - Net cash flow from operating activities for Q1 2023 was -347,648,507.87, an improvement from -956,933,116.45 in Q1 2022[32] - Cash inflow from investment activities increased to 227,257,579.68 in Q1 2023, compared to 168,822,735.36 in Q1 2022[33] - Net cash flow from financing activities was -878,583,116.52 in Q1 2023, significantly worse than -10,680,989.20 in Q1 2022[33] - Total cash and cash equivalents at the end of Q1 2023 decreased to 193,769,345.45 from 547,167,168.51 in Q1 2022[33] - Cash received from operating activities related to other business activities was 375,155,082.27 in Q1 2023, down from 468,379,505.52 in Q1 2022[32] - Cash paid for employee compensation increased to 13,441,337.71 in Q1 2023 from 10,225,465.14 in Q1 2022[32] - Cash inflow from loans in Q1 2023 was 876,000,000.00, a decrease from 1,360,000,000.00 in Q1 2022[33] - Cash outflow for debt repayment rose to 1,712,367,200.00 in Q1 2023, compared to 873,798,400.26 in Q1 2022[33] - The net increase in cash and cash equivalents for Q1 2023 was -1,004,878,951.65, compared to -928,332,421.70 in Q1 2022[33] Assets and Liabilities - Total assets at the end of the reporting period were CNY 35,417,246,461.81, a decrease of 1.68% from the end of the previous year[5] - Total assets as of March 31, 2023, were RMB 35,417,246,461.81, down from RMB 36,023,021,753.09[14] - Total liabilities decreased to RMB 16,676,022,709.47 from RMB 18,080,738,769.39, a reduction of 7.8%[15] - Total current assets decreased to CNY 6,171,649,506.42 from CNY 6,995,556,470.48, a decline of approximately 11.8%[26] - Non-current assets totaled CNY 12,245,482,175.94, down from CNY 12,408,506,078.98, reflecting a decrease of about 1.3%[26] - Total assets amounted to CNY 18,417,131,682.36, a reduction of approximately 5.1% compared to CNY 19,404,062,549.46[26] - Total current liabilities decreased to CNY 6,290,470,518.98 from CNY 7,161,968,064.50, representing a decline of around 12.1%[26] Shareholder Equity - Shareholders' equity attributable to shareholders increased by 4.69% to CNY 15,742,386,028.25 compared to the end of the previous year[5] - Shareholders' equity increased to RMB 18,741,223,752.34 from RMB 17,942,282,983.70, an increase of 4.4%[15] Operational Costs and Expenses - Total operating costs for Q1 2023 were RMB 5,431,915,788.85, up 16.4% from RMB 4,664,211,013.43 in Q1 2022[17] - The company’s total operating expenses increased to ¥5,663,257,165.43, compared to ¥5,047,209,640.40 in Q1 2022[22] - Research and development expenses rose to ¥285,358,236.04, up 32.6% from ¥215,047,329.07 in Q1 2022[18] - Research and development expenses rose to CNY 2,989,495.66 from CNY 2,254,103.21, an increase of about 32.6%[29] Future Outlook - The increase in net profit after deducting non-recurring gains and losses was attributed to the recovery of hospital services and increased demand for related medications[6] - The company plans to continue expanding its market presence and investing in new product development[16]